Acquisition of rifampin resistance in pulmonary tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 4, 2017, Pages

  Kayigire, Xavier A ^a,b   Friedrich, Sven O ^a,b   Van Der Merwe, Lize ^b   Diacon, Andreas H ^a,b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b TASK APPLIED SCIENCE   (South Africa)

Author keywords

Resistance; Rifampin; Treatment; Tuberculosis

Indexed keywords

RIFAMPICIN; BACTERIAL PROTEIN; DNA DIRECTED RNA POLYMERASE; RPOB PROTEIN, MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL LOAD; DRUG DISTRIBUTION; HUMAN; LUNG TUBERCULOSIS; MONOTHERAPY; MUTATION RATE; MYCOBACTERIUM; PRIORITY JOURNAL; ANTIBIOTIC RESISTANCE; BACTERIAL COUNT; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; STATISTICAL MODEL; TISSUE DISTRIBUTION; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; BACTERIAL LOAD; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION; HUMANS; MODELS, STATISTICAL; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TISSUE DISTRIBUTION; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 85016966549     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02220-16     Document Type: Article

References (18)

1. Gillespie SH. 2002. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 46:267-274. https://doi.org/10.1128/AAC.46.2.267-274.2002.
2. Colijn C, Cohen T, Ganesh A, Murray M. 2011. Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PLoS One 6:e18327. https://doi.org/10.1371/journal.pone.0018327.
3. Davies J, Davies D. 2010. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74:417-433. https://doi.org/10.1128/MMBR.00016-10.
4. David HL. 1970. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 20:810-814.
5. Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T, Johnston JC, Gardy J, Lipsitch M, Fortune SM. 2013. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 45:784-790. https://doi.org/10.1038/ng.2656.
6. Johnson R, Warren RM, van der Spuy GD, Gey van Pittius NC, Theron D, Streicher EM, Bosman M, Coetzee GJ, van Helden PD, Victor TC. 2010. Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. Int J Tuberc Lung Dis 14:119-121.
7. Strauss OJ, Warren RM, Jordaan A, Streicher EM, Hanekom M, Falmer AA, Albert H, Trollip A, Hoosain E, van Helden PD, Victor TC. 2008. Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. J Clin Microbiol 46:1514-1516. https://doi.org/10.1128/JCM.01938-07.
8. Shimao T. 1987. Drug resistance in tuberculosis control. Tubercle 68:5-18. https://doi.org/10.1016/S0041-3879(87)80014-4.
9. World Health Organization. 2010. Treatment of tuberculosis: guidelines for national programmes. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/features-archive/new-treatment-guidelines-may2010/en/.
10. Jindani A, Nunn AJ, Enarson DA. 2004. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 364:1244-1251. https://doi.org/10.1016/S0140-6736(04)17141-9.
11. Miles SH, Maat RB. 1984. A successful supervised outpatient short-course tuberculosis treatment program in an open refugee camp on the Thai-Cambodian border. Am Rev Respir Dis 130:827-830.
12. Gumbo T, Pasipanodya JG, Romero K, Hanna D, Nuermberger E. 2015. Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes. Clin Infect Dis 61(Suppl 1):S25-S31. https://doi.org/10.1093/cid/civ427.
13. Dartois V. 2014. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol 12:159-167. https://doi.org/10.1038/nrmicro3200.
14. Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, Chen C, Kaya F, Weiner DM, Chen P-Y, Song T, Lee M, Shim TS, Cho JS, Kim W, Cho SN, Olivier KN, Barry CE, Dartois V. 2015. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med 21:1223-1227. https://doi.org/10.1038/nm.3937.
15. Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, Nacy CA, Aarnoutse RE, Boeree MJ, Gillespie SH, Venter A, Henne S, Rachow A, Phillips PPJ, Hoelscher M, Diacon AH, Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA). 2015. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother 70:1558-1566. https://doi.org/10.1093/jac/dku553.
16. Hain Lifescience GmbH. 2012. GenoType MTBDRplus version 2.0. Product manual. Hain Lifescience GmbH, Nehren, Germany.
17. Canetti G, Rist N, Grosset J. 1963. Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation. Rev Tuberc Pneumol (Paris) 27:217-272. (In French.)
18. Hofmann-Thiel S, van Ingen J, Feldmann K, Turaev L, Uzakova GT, Murmusaeva G, van Soolingen D, Hoffmann H. 2009. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur Respir J 33:368-374. https://doi.org/10.1183/09031936.00089808.